{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:34:44Z","timestamp":1792708484127,"version":"4.5.0"},"reference-count":150,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100005277","name":"PHS","doi-asserted-by":"publisher","award":["DP1AG047744"],"award-info":[{"award-number":["DP1AG047744"]}],"id":[{"id":"10.13039\/100005277","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological Psychiatry"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.biopsych.2015.12.028","type":"journal-article","created":{"date-parts":[[2016,1,18]],"date-time":"2016-01-18T11:46:38Z","timestamp":1453117598000},"page":"67-77","source":"Crossref","is-referenced-by-count":146,"title":["Novel Dopamine Therapeutics for Cognitive Deficits in Schizophrenia"],"prefix":"10.1016","volume":"81","author":[{"given":"Amy F.T.","family":"Arnsten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ragy R.","family":"Girgis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Mailman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopsych.2015.12.028_bib1","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1176\/appi.ajp.2008.08060806","article-title":"Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: A randomized, open-label clinical trial (EUFEST)","volume":"166","author":"Davidson","year":"2009","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2015.12.028_bib2","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1093\/oxfordjournals.schbul.a033374","article-title":"The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: A review and meta-analysis","volume":"25","author":"Keefe","year":"1999","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.biopsych.2015.12.028_bib3","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1126\/science.112679","article-title":"Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey","volume":"205","author":"Brozoski","year":"1979","journal-title":"Science"},{"key":"10.1016\/j.biopsych.2015.12.028_bib4","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1038\/mp.2014.171","article-title":"Distinctive transcriptome alterations of prefrontal pyramidal neurons in schizophrenia and schizoaffective disorder","volume":"20","author":"Arion","year":"2015","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2015.12.028_bib5","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1124\/pr.115.010512","article-title":"Dopamine\u2019s actions in primate prefrontal cortex: Challenges for treating cognitive disorders","volume":"67","author":"Arnsten","year":"2015","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.biopsych.2015.12.028_bib6","doi-asserted-by":"crossref","first-page":"12078","DOI":"10.1073\/pnas.1307849110","article-title":"Nicotinic \u03b17 receptors enhance NMDA cognitive circuits in dorsolateral prefrontal cortex","volume":"110","author":"Yang","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.biopsych.2015.12.028_bib7","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1471-4159.2010.06720.x","article-title":"Dopamine D(1) receptor-mediated enhancement of NMDA receptor trafficking requires rapid PKC-dependent synaptic insertion in the prefrontal neurons","volume":"114","author":"Li","year":"2010","journal-title":"J Neurochem"},{"key":"10.1016\/j.biopsych.2015.12.028_bib8","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1126\/science.287.5460.2020","article-title":"Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation","volume":"287","author":"Castner","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.biopsych.2015.12.028_bib9","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/S0022-3565(25)21599-3","article-title":"SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems","volume":"226","author":"Iorio","year":"1983","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.biopsych.2015.12.028_bib10","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1527-3458.2001.tb00207.x","article-title":"SCH 23390: The first selective dopamine D1-like receptor antagonist","volume":"7","author":"Bourne","year":"2001","journal-title":"CNS Drug Rev"},{"key":"10.1016\/j.biopsych.2015.12.028_bib11","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1021\/jm00128a038","article-title":"Synthesis and receptor affinities of some conformationally restricted analogs of the dopamine D1 selective ligand (5R)-8-chloro-2,3,4,5-tetrahydro-3-methyl-5-phenyl-1H-3-benzazepin-7-ol","volume":"32","author":"Berger","year":"1989","journal-title":"J Med Chem"},{"key":"10.1016\/j.biopsych.2015.12.028_bib12","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/BF02246068","article-title":"Lack of apparent antipsychotic effect of the D1-dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients","volume":"121","author":"Karlsson","year":"1995","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopsych.2015.12.028_bib13","first-page":"93","article-title":"A pilot study of the safety and tolerance of SCH 39166 in patients with schizophrenia","volume":"23","author":"Labelle","year":"1998","journal-title":"J Psychiatry Neurosci"},{"key":"10.1016\/j.biopsych.2015.12.028_bib14","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/BF02246069","article-title":"Differential effects of the D1-DA receptor antagonist SCH39166 on positive and negative symptoms of schizophrenia","volume":"121","author":"Den Boer","year":"1995","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopsych.2015.12.028_bib15","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/BF02246070","article-title":"An open trial of the D1 antagonist SCH 39166 in six cases of acute psychotic states","volume":"121","author":"de Beaurepaire","year":"1995","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopsych.2015.12.028_bib16","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s002130100725","article-title":"Effects of ecopipam, a selective dopamine D1 antagonist, on smoked cocaine self-administration by humans","volume":"155","author":"Haney","year":"2001","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopsych.2015.12.028_bib17","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1038\/oby.2007.205","article-title":"Randomized controlled trials of the D1\/D5 antagonist ecopipam for weight loss in obese subjects","volume":"15","author":"Astrup","year":"2007","journal-title":"Obesity"},{"key":"10.1016\/j.biopsych.2015.12.028_bib18","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.bbr.2006.05.008","article-title":"Effect of dopamine D1 receptor antagonist SCH23390 and D1 agonist A77636 on active allothetic place avoidance, a spatial cognition task","volume":"172","author":"Stuchlik","year":"2006","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.biopsych.2015.12.028_bib19","first-page":"2061","article-title":"Carbon-11-NNC 112: A radioligand for PET examination of striatal and neocortical D1-dopamine receptors","volume":"39","author":"Halldin","year":"1998","journal-title":"J Nucl Med"},{"key":"10.1016\/j.biopsych.2015.12.028_bib20","first-page":"81","article-title":"PET imaging of D1 receptors in striatal subdivisions in schizophrenia","volume":"50","author":"Abi-Dargham","year":"2009","journal-title":"J Nucl Med Meeting Abstracts"},{"key":"10.1016\/j.biopsych.2015.12.028_bib21","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1523\/JNEUROSCI.22-09-03708.2002","article-title":"Prefrontal dopamine D1 receptors and working memory in schizophrenia","volume":"22","author":"Abi-Dargham","year":"2002","journal-title":"J Neurosci"},{"key":"10.1016\/j.biopsych.2015.12.028_bib22","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1126\/science.1166102","article-title":"Changes in cortical dopamine D1 receptor binding associated with cognitive training","volume":"323","author":"McNab","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.biopsych.2015.12.028_bib23","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.biopsych.2009.07.008","article-title":"Tolcapone effects on gating, working memory, and mood interact with the synonymous catechol-O-methyltransferase rs4818c\/g polymorphism","volume":"66","author":"Roussos","year":"2009","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2015.12.028_bib24","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/00008571-199606000-00007","article-title":"Human catechol-O-methyltransferase pharmacogenetics: Description of a functional polymorphism and its potential application to neuropsychiatric disorders","volume":"6","author":"Lachman","year":"1996","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.biopsych.2015.12.028_bib25","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1124\/jpet.102.042846","article-title":"Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: A comparative study in the rat","volume":"304","author":"Forsberg","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"issue":"815\u2013825","key":"10.1016\/j.biopsych.2015.12.028_bib26","first-page":"e856","article-title":"Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson\u2019s disease","volume":"22","author":"Ferreira","year":"2015","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.biopsych.2015.12.028_bib27","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1517\/14740338.4.1.69","article-title":"Tolcapone in Parkinson\u2019s disease: Liver toxicity and clinical efficacy","volume":"4","author":"Borges","year":"2005","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.biopsych.2015.12.028_bib28","doi-asserted-by":"crossref","first-page":"535","DOI":"10.2165\/00023210-200721070-00002","article-title":"Treatment of cognitive deficits associated with schizophrenia: Potential role of catechol-O-methyltransferase inhibitors","volume":"21","author":"Apud","year":"2007","journal-title":"CNS Drugs"},{"key":"10.1016\/j.biopsych.2015.12.028_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/jpet.106.104463","article-title":"Functional selectivity and classical concepts of quantitative pharmacology","volume":"320","author":"Urban","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.biopsych.2015.12.028_bib30","series-title":"Dopamine Receptor Subtypes: From Basic Science to Clinical Application","first-page":"64","article-title":"Functional effects of novel dopamine ligands: Dihydrexidine and Parkinson\u2019s disease as a first step","author":"Mailman","year":"1998"},{"key":"10.1016\/j.biopsych.2015.12.028_bib31","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/npp.2009.117","article-title":"Ligand functional selectivity advances our understanding of drug mechanisms and drug discovery","volume":"35","author":"Mailman","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2015.12.028_bib32","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1124\/jpet.301.3.1166","article-title":"Functional selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D2 receptors linked to adenylate cyclase","volume":"301","author":"Mottola","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.biopsych.2015.12.028_bib33","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1124\/jpet.301.3.1179","article-title":"Functional selectivity of dopamine receptor agonists. II. Actions of dihydrexidine in D2L receptor-transfected MN9D cells and pituitary lactotrophs","volume":"301","author":"Kilts","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.biopsych.2015.12.028_bib34","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1124\/mol.66.1.97","article-title":"Functional selectivity of D2 receptor ligands in a Chinese hamster ovary hD2L cell line: Evidence for induction of ligand-specific receptor states","volume":"66","author":"Gay","year":"2004","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.biopsych.2015.12.028_bib35","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S0140-6736(88)91755-2","article-title":"Subcutaneous apomorphine in Parkinson\u2019s disease","volume":"1","author":"Poewe","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.biopsych.2015.12.028_bib36","first-page":"656","article-title":"Continuous subcutaneous apomorphine infusions for fluctuating Parkinson\u2019s disease. Long-term follow-up in 18 patients","volume":"60","author":"Poewe","year":"1993","journal-title":"Adv Neurol"},{"key":"10.1016\/j.biopsych.2015.12.028_bib37","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1136\/jnnp.64.5.573","article-title":"Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson\u2019s disease","volume":"64","author":"Colzi","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.biopsych.2015.12.028_bib38","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/mds.870080208","article-title":"Subcutaneous apomorphine in Parkinson\u2019s disease: Response to chronic administration for up to five years","volume":"8","author":"Hughes","year":"1993","journal-title":"Mov Disord"},{"key":"10.1016\/j.biopsych.2015.12.028_bib39","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1136\/jnnp.53.11.1015","article-title":"Intranasal apomorphine: A new treatment in Parkinson\u2019s disease [letter]","volume":"53","author":"Kapoor","year":"1990","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.biopsych.2015.12.028_bib40","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1001\/archneur.1992.00530290064013","article-title":"Intranasal apomorphine in parkinsonian on-off fluctuations","volume":"49","author":"Van Laar","year":"1992","journal-title":"Arch Neurol"},{"key":"10.1016\/j.biopsych.2015.12.028_bib41","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/mds.870110607","article-title":"A new sublingual formulation of apomorphine in the treatment of patients with Parkinson\u2019s disease","volume":"11","author":"Van Laar","year":"1996","journal-title":"Mov Disord"},{"key":"10.1016\/j.biopsych.2015.12.028_bib42","first-page":"75","article-title":"The affinities of ergot compounds for dopamine agonist and dopamine antagonist receptor sites","volume":"23","author":"Goldstein","year":"1980","journal-title":"Adv Biochem Psychopharmacol"},{"key":"10.1016\/j.biopsych.2015.12.028_bib43","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/0024-3205(91)90074-L","article-title":"Pergolide: A dopamine agonist at both D1 and D2 receptors","volume":"49","author":"Fuller","year":"1991","journal-title":"Life Sci"},{"key":"10.1016\/j.biopsych.2015.12.028_bib44","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0165-6147(90)90249-8","article-title":"Dopamine receptor subtypes: Beyond the D1\/D2 classification","volume":"11","author":"Andersen","year":"1990","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.biopsych.2015.12.028_bib45","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0014-2999(88)90322-6","article-title":"The D-1 dopamine receptor partial agonist, CY 208-243, exhibits antiparkinsonian activity in the MPTP-treated marmoset","volume":"156","author":"Temlett","year":"1988","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.biopsych.2015.12.028_bib46","first-page":"119","article-title":"The effects of D1 and D2 dopamine receptor agonist and antagonist on parkinsonism in chronic MPTP-treated monkeys","volume":"60","author":"Nomoto","year":"1993","journal-title":"Adv Neurol"},{"key":"10.1016\/j.biopsych.2015.12.028_bib47","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/mds.870080205","article-title":"Effect of adding the D1 agonist CY 208-243 to chronic bromocriptine treatment. I: Evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptors","volume":"8","author":"Gomez-Mancilla","year":"1993","journal-title":"Mov Disord"},{"key":"10.1016\/j.biopsych.2015.12.028_bib48","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1212\/WNL.39.6.856","article-title":"A double-blind, placebo-controlled, dose-ranging study to investigate the safety and efficacy of CY 208-243 in patients with Parkinson\u2019s disease","volume":"39","author":"Tsui","year":"1989","journal-title":"Neurology"},{"key":"10.1016\/j.biopsych.2015.12.028_bib49","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.pharmthera.2011.03.008","article-title":"Serotonin receptors and heart valve disease--it was meant 2B","volume":"132","author":"Hutcheson","year":"2011","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.biopsych.2015.12.028_bib50","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0014-2999(78)90057-2","article-title":"Studies on renal dopamine receptors with a new agonist","volume":"51","author":"Pendleton","year":"1978","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.biopsych.2015.12.028_bib51","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/0014-2999(78)90148-6","article-title":"The central effects of a novel dopamine agonist","volume":"50","author":"Setler","year":"1978","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.biopsych.2015.12.028_bib52","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1021\/jm00348a017","article-title":"Absolute stereochemistry and dopaminergic activity of enantiomers of 2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine","volume":"25","author":"Kaiser","year":"1982","journal-title":"J Med Chem"},{"key":"10.1016\/j.biopsych.2015.12.028_bib53","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/med.2610050202","article-title":"Dopamine receptors: Functions, subtypes and emerging concepts","volume":"5","author":"Kaiser","year":"1985","journal-title":"Med Res Rev"},{"key":"10.1016\/j.biopsych.2015.12.028_bib54","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0014-2999(03)02008-9","article-title":"Receptor affinities of dopamine D1 receptor-selective novel phenylbenzazepines","volume":"474","author":"Neumeyer","year":"2003","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.biopsych.2015.12.028_bib55","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0014-2999(93)90076-T","article-title":"Dopamine D1 receptors: Efficacy of full (dihydrexidine) vs. partial (SKF38393) agonists in primates vs. rodents","volume":"242","author":"Watts","year":"1993","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.biopsych.2015.12.028_bib56","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/0028-3908(95)00014-W","article-title":"\"Full\" dopamine D1 agonists in human caudate: Biochemical properties and therapeutic implications","volume":"34","author":"Gilmore","year":"1995","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopsych.2015.12.028_bib57","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/syn.890210211","article-title":"Spare receptors and intrinsic activity: Studies with D1 dopamine receptor agonists","volume":"21","author":"Watts","year":"1995","journal-title":"Synapse"},{"key":"10.1016\/j.biopsych.2015.12.028_bib58","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.schres.2007.03.011","article-title":"A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D(1) agonist, is safe and tolerated in patients with schizophrenia","volume":"93","author":"George","year":"2007","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2015.12.028_bib59","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0014-2999(93)90718-W","article-title":"Grooming and vacuous chewing induced by SK&F 83959, an agonist of dopamine \u2019D1-like\u2019 receptors that inhibits dopamine-sensitive adenylyl cyclase","volume":"234","author":"Downes","year":"1993","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.biopsych.2015.12.028_bib60","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/BF02246102","article-title":"Differential anti-parkinsonian effects of benzazepine D 1 dopamine agonists with varying efficacies in the MPTP-treated common marmoset","volume":"117","author":"Gnanalingham","year":"1995","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopsych.2015.12.028_bib61","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/BF02246103","article-title":"The differential behavioural effects of benzazepine D1 dopamine agonists with varying efficacies, co-administered with quinpirole in primate and rodent models of Parkinson\u2019s disease","volume":"117","author":"Gnanalingham","year":"1995","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopsych.2015.12.028_bib62","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.neuroscience.2014.11.017","article-title":"Regulation of c-fos expression by the dopamine D1-D2 receptor heteromer","volume":"285","author":"Perreault","year":"2015","journal-title":"Neuroscience"},{"key":"10.1016\/j.biopsych.2015.12.028_bib63","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.neuropharm.2014.05.042","article-title":"SKF-83959 is not a highly-biased functionally selective D1 dopamine receptor ligand with activity at phospholipase C","volume":"86","author":"Lee","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopsych.2015.12.028_bib64","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1124\/jpet.114.214411","article-title":"Dopamine D1 receptor signaling: Does GalphaQ-Phospholipase C actually play a role?","volume":"351","author":"Lee","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.biopsych.2015.12.028_bib65","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/mp.2014.166","article-title":"Evidence against dopamine D1\/D2 receptor heteromers","volume":"20","author":"Frederick","year":"2015","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2015.12.028_bib66","first-page":"1582","article-title":"Parkinson\u2019s disease and D1 dopamine receptors","volume":"2","author":"Mailman","year":"2001","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.biopsych.2015.12.028_bib67","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/BF02252620","article-title":"Seizure promotion by D1 agonists does not correlate with other dopaminergic properties","volume":"6","author":"Starr","year":"1993","journal-title":"J Neural Transm Park Dis Dement Sect"},{"key":"10.1016\/j.biopsych.2015.12.028_bib68","first-page":"315","article-title":"Effects of modifications of the 4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinoline structure on dopamine sensitive rat retinal adenylate cyclase activity","volume":"11","author":"Truex","year":"1985","journal-title":"Society for Neuroscience Abstracts"},{"key":"10.1016\/j.biopsych.2015.12.028_bib69","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/0014-2999(87)90240-8","article-title":"Thienopyridine derivatives identified as the first selective, full efficacy, dopamine D1 receptor agonists","volume":"137","author":"Andersen","year":"1987","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.biopsych.2015.12.028_bib70","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0014-2999(89)90690-0","article-title":"Dihydrexidine, a novel selective high potency full dopamine D-1 receptor agonist","volume":"166","author":"Lovenberg","year":"1989","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.biopsych.2015.12.028_bib71","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1111\/j.1471-4159.1991.tb06352.x","article-title":"D1 dopamine receptors of NS20Y neuroblastoma cells are functionally similar to rat striatal D1 receptors","volume":"57","author":"Lovenberg","year":"1991","journal-title":"J Neurochem"},{"key":"10.1016\/j.biopsych.2015.12.028_bib72","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0022-3565(25)10762-3","article-title":"Dihydrexidine, a novel full efficacy D1 dopamine receptor agonist","volume":"262","author":"Mottola","year":"1992","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.biopsych.2015.12.028_bib73","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1021\/jm00168a034","article-title":"trans-10,11-Dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine: A highly potent selective dopamine D1 full agonist","volume":"33","author":"Brewster","year":"1990","journal-title":"J Med Chem"},{"key":"10.1016\/j.biopsych.2015.12.028_bib74","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/0014-2999(91)90508-N","article-title":"Dihydrexidine, a full dopamine D1 agonist, reduces MPTP-induced parkinsonism in monkeys","volume":"199","author":"Taylor","year":"1991","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.biopsych.2015.12.028_bib75","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/BF02245056","article-title":"Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys","volume":"116","author":"Arnsten","year":"1994","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopsych.2015.12.028_bib76","first-page":"187","article-title":"Behavioral effects in the rat of dihydrexidine, a high-potency, full-efficacy D1 dopamine receptor agonist","volume":"5","author":"Darney","year":"1991","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2015.12.028_bib77","doi-asserted-by":"crossref","first-page":"40S","DOI":"10.1093\/ajh\/3.6.40S","article-title":"A68930: A potent and specific agonist for the D-1 dopamine receptor","volume":"3","author":"Kebabian","year":"1990","journal-title":"Am J Hyperten"},{"key":"10.1016\/j.biopsych.2015.12.028_bib78","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0014-2999(92)90556-J","article-title":"A-77636: A potent and selective dopamine D1 receptor agonist with antiparkinsonian activity in marmosets","volume":"229","author":"Kebabian","year":"1992","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.biopsych.2015.12.028_bib79","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0014-2999(91)90459-4","article-title":"A68930: A potent agonist selective for the dopamine D1 receptor","volume":"199","author":"DeNinno","year":"1991","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.biopsych.2015.12.028_bib80","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0022-3565(25)39350-X","article-title":"Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- exposed monkeys","volume":"267","author":"Blanchet","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.biopsych.2015.12.028_bib81","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/mds.870100606","article-title":"Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus)","volume":"10","author":"Pearce","year":"1995","journal-title":"Mov Disord"},{"key":"10.1016\/j.biopsych.2015.12.028_bib82","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0014-2999(93)90840-E","article-title":"Effects of repeated dopamine D 1 receptor stimulation on rotation and c-fos expression","volume":"235","author":"Asin","year":"1993","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.biopsych.2015.12.028_bib83","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0014-2999(91)90670-L","article-title":"Rapid reversal of denervation supersensitivity of dopamine D1 receptors by l-dopa or a novel dopamine D1 receptor agonist, A68930","volume":"200","author":"Britton","year":"1991","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.biopsych.2015.12.028_bib84","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0014-2999(96)00309-3","article-title":"Dopamine D 1 receptor desensitization profile in MPTP-lesioned primates","volume":"309","author":"Blanchet","year":"1996","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.biopsych.2015.12.028_bib85","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.1021\/jm00018a002","volume":"38","author":"Michaelides","year":"1995","journal-title":"J Med Chem"},{"key":"10.1016\/j.biopsych.2015.12.028_bib86","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S0022-3565(25)12244-1","article-title":"ABT-431: The diacetyl prodrug of A-86929, a potent and selective dopamine D 1 receptor agonist: In vitro characterization and effects in animal models of Parkinson\u2019s disease","volume":"276","author":"Shiosaki","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.biopsych.2015.12.028_bib87","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1002\/1531-8249(199906)45:6<736::AID-ANA7>3.0.CO;2-F","article-title":"ABT-431, a D1 receptor agonist prodrug, has efficacy in Parkinson\u2019s disease","volume":"45","author":"Rascol","year":"1999","journal-title":"Ann Neurol"},{"key":"10.1016\/j.biopsych.2015.12.028_bib88","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1021\/jm950707+","article-title":"9-Dihydroxy-2,3,7,11b-tetrahydro-1H-naph[1,2,3-de]isoquinoline: A potent full dopamine D1 agonist containing a rigid-beta-phenyldopamine pharmacophore","volume":"39","author":"Ghosh","year":"1996","journal-title":"J Med Chem"},{"key":"10.1016\/j.biopsych.2015.12.028_bib89","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S0022-3565(24)38751-8","article-title":"Dinapsoline: Characterization of a D1 dopamine receptor agonist in a rat model of Parkinson\u2019s disease","volume":"296","author":"Gulwadi","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.biopsych.2015.12.028_bib90","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0022-3565(24)37594-9","article-title":"Homologous desensitization of the D1A dopamine receptor: Efficacy in causing desensitization dissociates from both receptor occupancy and functional potency","volume":"286","author":"Lewis","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.biopsych.2015.12.028_bib91","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.neuropharm.2006.08.028","article-title":"Functional selectivity of dopamine D(1) receptor agonists in regulating the fate of internalized receptors","volume":"52","author":"Ryman-Rasmussen","year":"2007","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopsych.2015.12.028_bib92","first-page":"339","article-title":"Effects of the full dopamine D1 receptor agonist dihydrexidine in Parkinson\u2019s disease","volume":"21","author":"Blanchet","year":"1998","journal-title":"Clin Neuropharmacol"},{"issue":"suppl 1","key":"10.1016\/j.biopsych.2015.12.028_bib93","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1291\/hypres.18.SupplementI_S23","article-title":"Pharmacological characterisation and autoradiographic localisation of dopamine receptor subtypes in the cardiovascular system and in the kidney","volume":"18","author":"Amenta","year":"1995","journal-title":"Hypertens Res"},{"key":"10.1016\/j.biopsych.2015.12.028_bib94","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.schres.2007.03.033","article-title":"A single 20 mg dose of the full D(1) dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia","volume":"94","author":"Mu","year":"2007","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2015.12.028_bib95","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/npp.2014.192","article-title":"Effects of the D1 dopamine receptor agonist dihydrexidine (DAR-0100A) on working memory in schizotypal personality disorder","volume":"40","author":"Rosell","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2015.12.028_bib96","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/S0022-3565(25)12376-8","article-title":"Persistent activation of the dopamine D 1 receptor contributes to prolonged receptor desensitization: Studies with A-77636","volume":"276","author":"Lin","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.biopsych.2015.12.028_bib97","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1126\/science.3854","article-title":"Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs","volume":"192","author":"Creese","year":"1976","journal-title":"Science"},{"key":"10.1016\/j.biopsych.2015.12.028_bib98","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1177\/070674379704200205","article-title":"The history of the psychopharmacology of schizophrenia","volume":"42","author":"Lehmann","year":"1997","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.biopsych.2015.12.028_bib99","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.mp.4001556","article-title":"Treatments for schizophrenia: A critical Review of pharmacology and mechanisms of action of antipsychotic drugs","volume":"10","author":"Miyamoto","year":"2005","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2015.12.028_bib100","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/BF00216006","article-title":"Provocative tests with psychostimulant drugs in schizophrenia","volume":"91","author":"Lieberman","year":"1987","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.biopsych.2015.12.028_bib101","doi-asserted-by":"crossref","first-page":"9235","DOI":"10.1073\/pnas.93.17.9235","article-title":"Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects","volume":"93","author":"Laruelle","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.biopsych.2015.12.028_bib102","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1176\/ajp.155.6.761","article-title":"Increased striatal dopamine transmission in schizophrenia: Confirmation in a second cohort","volume":"155","author":"Abi-Dargham","year":"1998","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2015.12.028_bib103","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1073\/pnas.94.6.2569","article-title":"Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method","volume":"94","author":"Breier","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.biopsych.2015.12.028_bib104","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/S0140-6736(95)91801-9","article-title":"Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients","volume":"346","author":"Hietala","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.biopsych.2015.12.028_bib105","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1001\/archpsyc.61.2.134","article-title":"Presynaptic dopaminergic dysfunction in schizophrenia: A positron emission tomographic [F-18]fluorodopa study","volume":"61","author":"McGowan","year":"2004","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2015.12.028_bib106","doi-asserted-by":"crossref","first-page":"11651","DOI":"10.1073\/pnas.91.24.11651","article-title":"Elevated dopa decarboxylase activity in living brain of patients with psychosis","volume":"91","author":"Reith","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.biopsych.2015.12.028_bib107","doi-asserted-by":"crossref","first-page":"8104","DOI":"10.1073\/pnas.97.14.8104","article-title":"Increased baseline occupancy of D2 receptors by dopamine in schizophrenia","volume":"97","author":"Abi-Dargham","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.biopsych.2015.12.028_bib108","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.eurpsy.2004.11.003","article-title":"Mechanisms of action of second generation antipsychotic drugs in schizophrenia: Insights from brain imaging studies","volume":"20","author":"Abi-Dargham","year":"2005","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.biopsych.2015.12.028_bib109","doi-asserted-by":"crossref","first-page":"538","DOI":"10.4088\/JCP.v58n1205","article-title":"The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: Combined results of the North American trials","volume":"58","author":"Marder","year":"1997","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.biopsych.2015.12.028_bib110","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1176\/ajp.151.1.20","article-title":"Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia","volume":"151","author":"Breier","year":"1994","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2015.12.028_bib111","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1017\/S1461145703003651","article-title":"Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia","volume":"6","author":"Kasper","year":"2003","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.biopsych.2015.12.028_bib112","first-page":"28","article-title":"Assessing the effects of atypical antipsychotics on negative symptoms","volume":"59","author":"Meltzer","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.biopsych.2015.12.028_bib113","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1176\/ajp.154.6.799","article-title":"Does risperidone improve verbal working memory in treatment-resistant schizophrenia?","volume":"154","author":"Green","year":"1997","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2015.12.028_bib114","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S0006-3223(98)00088-2","article-title":"Risperidone vs. haloperidol on reaction time, manual dexterity, and motor learning in treatment-resistant schizophrenia patients","volume":"44","author":"Kern","year":"1998","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2015.12.028_bib115","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/S0006-3223(02)01370-7","article-title":"The neurocognitive effects of low-dose haloperidol: A two-year comparison with risperidone","volume":"51","author":"Green","year":"2002","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2015.12.028_bib116","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1176\/appi.ajp.161.6.985","article-title":"Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: A randomized, double-blind trial of olanzapine versus low doses of haloperidol","volume":"161","author":"Keefe","year":"2004","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2015.12.028_bib117","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.biopsych.2005.06.022","article-title":"Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis","volume":"59","author":"Keefe","year":"2006","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2015.12.028_bib118","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/archpsyc.64.6.633","article-title":"Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial","volume":"64","author":"Keefe","year":"2007","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2015.12.028_bib119","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1037\/0894-4105.11.3.437","article-title":"Is it possible to be schizophrenic yet neuropsychologically normal?","volume":"11","author":"Palmer","year":"1997","journal-title":"Neuropsychology"},{"key":"10.1016\/j.biopsych.2015.12.028_bib120","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1176\/appi.ajp.157.4.549","article-title":"Neuropsychology of first-episode schizophrenia: Initial characterization and clinical correlates","volume":"157","author":"Bilder","year":"2000","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2015.12.028_bib121","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/schbul\/18.3.387","article-title":"Developmental processes in schizophrenic disorders: Longitudinal studies of vulnerability and stress","volume":"18","author":"Nuechterlein","year":"1992","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.biopsych.2015.12.028_bib122","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1176\/ajp.153.3.321","article-title":"What are the functional consequences of neurocognitive deficits in schizophrenia?","volume":"153","author":"Green","year":"1996","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2015.12.028_bib123","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/oxfordjournals.schbul.a033430","article-title":"Neurocognitive deficits and functional outcome in schizophrenia: Are we measuring the \u201cright stuff\u201d?","volume":"26","author":"Green","year":"2000","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.biopsych.2015.12.028_bib124","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/286074a0","article-title":"Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats","volume":"286","author":"Pycock","year":"1980","journal-title":"Nature"},{"key":"10.1016\/j.biopsych.2015.12.028_bib125","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1001\/archpsyc.1987.01800190080012","article-title":"Implications of normal brain development for the pathogenesis of schizophrenia","volume":"44","author":"Weinberger","year":"1987","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2015.12.028_bib126","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1176\/ajp.148.11.1474","article-title":"Dopamine in schizophrenia: A review and reconceptualization","volume":"148","author":"Davis","year":"1991","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2015.12.028_bib127","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1126\/science.1825731","article-title":"D1 dopamine receptors in prefrontal cortex: Involvement in working memory","volume":"251","author":"Sawaguchi","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.biopsych.2015.12.028_bib128","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1152\/jn.1994.71.2.515","article-title":"The role of D1-dopamine receptor in working memory: Local injections of dopamine antagonists into the prefrontal cortex of rhesus monkeys performing an oculomotor delayed-response task","volume":"71","author":"Sawaguchi","year":"1994","journal-title":"J Neurophysiol"},{"key":"10.1016\/j.biopsych.2015.12.028_bib129","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1523\/JNEUROSCI.18-04-01613.1998","article-title":"D1 receptor modulation of hippocampal-prefrontal cortical circuits integrating spatial memory with executive functions in the rat","volume":"18","author":"Seamans","year":"1998","journal-title":"J Neurosci"},{"key":"10.1016\/j.biopsych.2015.12.028_bib130","doi-asserted-by":"crossref","first-page":"8528","DOI":"10.1523\/JNEUROSCI.17-21-08528.1997","article-title":"Supranormal stimulation of dopamine D1 receptors in the rodent prefrontal cortex impairs spatial working memory performance","volume":"17","author":"Zahrt","year":"1997","journal-title":"J Neurosci"},{"key":"10.1016\/j.biopsych.2015.12.028_bib131","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/026988119701100208","article-title":"Catecholamine regulation of the prefrontal cortex","volume":"11","author":"Arnsten","year":"1997","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.biopsych.2015.12.028_bib132","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1177\/1073858403252674","article-title":"Prefrontal DA transmission at D1 receptors and the pathology of schizophrenia","volume":"9","author":"Abi-Dargham","year":"2003","journal-title":"Neuroscientist"},{"key":"10.1016\/j.biopsych.2015.12.028_bib133","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/nn1846","article-title":"Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory","volume":"10","author":"Vijayraghavan","year":"2007","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.biopsych.2015.12.028_bib134","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1749-6632.1988.tb42117.x","article-title":"Mesocortical dopaminergic function and human cognition","volume":"537","author":"Weinberger","year":"1988","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.biopsych.2015.12.028_bib135","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0920-9964(94)90015-9","article-title":"Neuropsychological correlates of central monoamine function in chronic schizophrenia: Relationship between CSF metabolites and cognitive function","volume":"11","author":"Kahn","year":"1994","journal-title":"Schizophr Res"},{"key":"10.1016\/j.biopsych.2015.12.028_bib136","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1523\/JNEUROSCI.11-07-01907.1991","article-title":"The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia","volume":"11","author":"Daniel","year":"1991","journal-title":"J Neurosci"},{"key":"10.1016\/j.biopsych.2015.12.028_bib137","doi-asserted-by":"crossref","first-page":"6917","DOI":"10.1073\/pnas.111134598","article-title":"Effect of COMT Val108\/158 Met genotype on frontal lobe function and risk for schizophrenia","volume":"98","author":"Egan","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.biopsych.2015.12.028_bib138","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1176\/ajp.156.10.1580","article-title":"Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects","volume":"156","author":"Akil","year":"1999","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2015.12.028_bib139","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/S0006-3223(96)00116-3","article-title":"A postmortem study of frontal cortical dopamine D1 receptors in schizophrenics, psychiatric controls, and normal controls","volume":"40","author":"Knable","year":"1996","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2015.12.028_bib140","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1001\/archpsyc.1997.01830240045007","article-title":"Dopamine receptor transcript expression in striatum and prefrontal and occipital cortex. Focal abnormalities in orbitofrontal cortex in schizophrenia","volume":"54","author":"Meador-Woodruff","year":"1997","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2015.12.028_bib141","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1177\/0269881111409265","article-title":"Increased prefrontal cortical D1 receptors in drug naive patients with schizophrenia: A PET study with [11C]NNC112","volume":"26","author":"Abi-Dargham","year":"2012","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.biopsych.2015.12.028_bib142","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/385634a0","article-title":"Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET","volume":"385","author":"Okubo","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.biopsych.2015.12.028_bib143","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1176\/appi.ajp.159.5.761","article-title":"PET study of D(1) dopamine receptor binding in neuroleptic-naive patients with schizophrenia","volume":"159","author":"Karlsson","year":"2002","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.biopsych.2015.12.028_bib144","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1001\/jamapsychiatry.2014.2414","article-title":"Deficits in prefrontal cortical and extra-striatal dopamine release in schizophrenia: A PET fMRI study","volume":"72","author":"Slifstein","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.biopsych.2015.12.028_bib145","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1038\/npp.2010.5","article-title":"Pergolide treatment of cognitive deficits associated with schizotypal personality disorder: Continued evidence of the importance of the dopamine system in the schizophrenia spectrum","volume":"35","author":"McClure","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2015.12.028_bib146","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1021\/jm00041a025","article-title":"Dopaminergic benzo[a]phenanthridines: Resolution and pharmacological evaluation of the enantiomers of dihydrexidine, the full efficacy D1 dopamine receptor agonist","volume":"37","author":"Knoerzer","year":"1994","journal-title":"J Med Chem"},{"key":"10.1016\/j.biopsych.2015.12.028_bib147","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/jcbfm.2010.91","article-title":"Characterization of in vivo pharmacokinetic properties of the dopamine D1 receptor agonist DAR-0100A in nonhuman primates using PET with [11C] NNC112 and [11C] raclopride","volume":"31","author":"Slifstein","year":"2011","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.biopsych.2015.12.028_bib148","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1124\/jpet.115.224071","article-title":"Discovery of D1 dopamine receptor positive allosteric modulators (PAM): Characterization of pharmacology and identification of residues which regulate species selectivity","volume":"354","author":"Lewis","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.biopsych.2015.12.028_bib149","unstructured":"Beadle DB, Coates DA, Hao J Jr., Krushinski JH, Reinhard MR, Schaus JM, Wolfangel CD (2014): 3,4-dihydroisoquinolin-2(1h)-yl compounds. Available at: https:\/\/www.google.com\/patents\/WO2014193781A1?cl=en. Accessed February 8, 2016."},{"key":"10.1016\/j.biopsych.2015.12.028_bib150","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0022-3565(25)09624-7","article-title":"Partial and full dopamine D1 agonists produce comparable increases in ventral pallidal neuronal activity: contribution of endogenous dopamine","volume":"273","author":"Heidenreich","year":"1995","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322316000445?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322316000445?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:49:38Z","timestamp":1748738978000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006322316000445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":150,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S0006322316000445"],"URL":"https:\/\/doi.org\/10.1016\/j.biopsych.2015.12.028","relation":{},"ISSN":["0006-3223"],"issn-type":[{"value":"0006-3223","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]}}}